Raven Biosciences

Raven Biosciences leverages advanced in-silico technologies to design a wide range of molecular modalities. Their expertise spans small molecules, peptides, antibodies, enzymes, proteins, and nucleotides, providing comprehensive solutions in drug design.

The company is recognized for its collaborative approach and deep insights into AI, in-silico methods, and medicinal chemistry, which have proven valuable to numerous portfolio companies. Their focus on maximizing customer value is highlighted by testimonials from industry leaders.

Raven Biosciences has been a trusted partner in drug development programs, offering drug design expertise that supports innovation in drug discovery. Their EpiC platform is particularly noted for its ability to accurately identify and characterize epitopes, as demonstrated in the development of the phase 3 ready antibody, mitazalimab.

In addition to EpiC, the ChemX platform simplifies data management and model training for machine learning applications. It facilitates straightforward screening and provides explainability analyses to enhance understanding of structure/activity relationships.

• Designs molecules using cutting-edge in-silico technologies
• Expertise in small molecules, peptides, antibodies, enzymes, proteins, and nucleotides
• Collaborative and insightful approach with a focus on customer value
• Innovative platforms like EpiC and ChemX for drug discovery and data management